SS
MLYS icon

SBI Securities’s Mineralys Therapeutics MLYS Stock Holding History

SBI Securities’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.13K Sell
116
-1
-0.9% -$27 ﹤0.01% 2386
2026
Q1 		$3.17K Buy
117
+1
+0.9% +$29 ﹤0.01% 2230
2025
Q4 		$4.21K Sell
116
-1,010
-90% -$40.5K ﹤0.01% 2091
2025
Q3 		$42.7K Sell
1,126
-598
-35% -$12.9K ﹤0.01% 1152
2025
Q2 		$23.3K Buy
1,724
+134
+8% +$1.94K ﹤0.01% 1358
2025
Q1 		$25.2K Buy
1,590
+1,190
+298% +$13.7K ﹤0.01% 1245
2024
Q4 		$4.92K Buy
+400
New +$5.23K ﹤0.01% 1925

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SBI Securities's MLYS Position: Q2 2026 in Review

SBI Securities reduced its Mineralys Therapeutics (MLYS) stake by 0.85% in Q2 2026, selling an estimated $27 and leaving 116 shares worth $3.13K. The position accounts for ﹤0.01% of the portfolio, ranked #2386.

SBI Securities first reported a position in MLYS in Q4 2024 and has held it in 7 quarters since. The position peaked at $42.7K in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • SBI Securities held 116 shares of Mineralys Therapeutics worth $3.13K as of Q2 2026.
  • SBI Securities sold 1 Mineralys Therapeutics share in Q2 2026, an estimated $27.
  • Mineralys Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2386 holding.
  • SBI Securities first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Mineralys Therapeutics position peaked at $42.7K in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.